1
Return

Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial

delete2026-07-30
delete0
PRE
AI
P
Pablo Mora *
V
Vanita R Aroda
M
Marisse Asong
M
Matthias Blüher
A
Amanda‐Louise Fenger Carlander
M
Morten Kaltoft
L
Louise Nygaard Vilsen
J
Julio Rosenstock
DOI：10.1016/s0140-6736(26)01247-xdelete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Zenagamtide (formerly amycretin) is a unimolecular peptide agonist of GLP-1, amylin, and calcitonin receptors. We aimed to investigate the dose–response relationship with respect to the efficacy and safety of once-daily oral zenagamtide compared with placebo in adults with type 2 diabetes.

Journal

The Lancet cover
The Lancet
IF:
88.5
Papers:
5.4W
Citations:
34.8W

Organization

N
Novo Nordisk
Scholars:
4.2K
Papers: 2.7K
Citations: 31
L
leipzig university and university of leipzig medical center
Scholars:
2
Papers: 2
Citations: 0
H
harvard medical school
Scholars:
4.6K
Papers: 2.1K
Citations: 2
S
Southwestern Medical Center
Scholars:
23
Papers: 14
Citations: 7.7K
Cited Papers

Cited Papers

Citing Papers

Citing Papers